May 14th 2024
The phase 2 VERSATILE-002 trial evaluating Versamune HPV with pembrolizumab met its primary end point in patients with first-line recurrent metastatic head and neck squamous cell cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Studies Show Durable Activity of Pembrolizumab in Head and Neck Cancer
June 15th 2016Pembrolizumab (Keytruda), when studied in 2 clinical trials for the treatment of patients with pretreated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), showed an objective response rate (ORR) of 18%, according to findings presented at the 2016 ASCO Annual Meeting.
Read More
CAR Therapy Yields High Complete Response Rates in Adults with B-cell ALL in Phase I Trial
June 9th 2016Infusion with 19-28z chimeric antigen receptor (CAR) modified T-cells led to complete response (CR) rates of 77% to 90% and minimal residual disease (MRD)-CR rates of 68% to 70% in adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (B-ALL).
Read More
Nivolumab Monotherapy Improves Responses in Head and Neck Squamous Cell Carcinoma
June 9th 2016Nivolumab (Opdivo) monotherapy showed improved overall survival (OS) and objective response rates for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) compared with the investigator's choice of alternative therapy, according to data presented at the 2016 ASCO Annual Meeting.
Read More
Novel TKI Examined in Metastatic Breast Cancer Patients with HER2 Mutation
June 8th 2016Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.
Read More
Nivolumab Granted FDA Breakthrough Designation for Head and Neck Cancer
April 25th 2016Nivolumab (Opdivo) has been granted a breakthrough therapy by the FDA as a treatment for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) following a platinum-based therapy.
Read More
Pembrolizumab Granted FDA Priority Review for HNSCC
April 14th 2016The FDA has granted a priority review designation to pembrolizumab (Keytruda) as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) following a platinum-based chemotherapy, according to a statement from Merck, the company developing the PD-1 inhibitor.
Read More
Cetuximab Improves Long-Term Disease Control in HPV-Negative HNSCC
April 7th 2016Adding cetuximab (Erbitux) to induction chemotherapy and hyperfractionated or accelerated chemoradiation therapy produced long-term control for patients with HPV-, locoregionally advanced head and neck squamous cell carcinoma with a poor prognosis.
Read More
Expert Says Lenvatinib Is Standard Frontline Option for RAI-Refractory DTC
April 6th 2016The multikinase inhibitor lenvatinib (Lenvima) has quickly become the frontline standard of care for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), just one year following its initial approval, according to Renato Martins, MD.
Read More
ACS Committee Generates New Guideline for Survivorship Care in Head and Neck Cancer
March 28th 2016The panel, which included experts in oncology, dentistry, nursing, speech pathology, and primary care, conducted a systematic literature review to develop these consensus-based management strategies for HNC survivors. Their search identified 2081 articles, of which 184 were ultimately included in the evidence base.
Read More
Dr. Maria E. Cabanillas on Reducing Time to Treatment for Anaplastic Thyroid Cancer
March 10th 2016Cabanillas says her and her team set a goal of reducing the time between when they are contacted about a patient with anaplastic thyroid cancer, and when the patient is given an appointment time, to fewer than 5 business days.
Watch
Dr. Jose P. Zevallos on Molecular Testing for Smokers With HPV+ Oropharyngeal SCC
March 8th 2016Zevallos says that while HPV-positive oropharyngeal SCC has a positive outcome for patients, smoking status should be taken into account for these patients when making a decision to deintensify therapy.
Watch
Dr. James Melotek on Cetuximab/Chemotherapy Combinations in Head and Neck Cancer
March 8th 2016Melotek says the trial's primary endpoint was comparison of efficacy when cetuximab is added to both therapies with historical control, with a secondary endpoint being further investigation of the usefulness of both chemotherapy platforms.
Watch
Dr. Tanguy Seiwert on the Increasing Efficacy of Immunotherapies in Head and Neck Cancer
March 5th 2016Seiwert says in general, immunotherapies produce a response rate of between 20- to 25%, 1 in 4 patients respond, and the treatment type is equally effective in both HPV-positive and HPV-negative disease.
Watch
Dr. Ezra Cohen on Siltuximab Combinations in Head and Neck Squamous Cell Carcinoma
March 4th 2016The two platforms involved in the study were the FHX regimen and a cisplatin radiation approach with accelerated radiation. Siltuximab was also used in the study as induction chemotherapy alongside carboplatin and paclitaxel.
Watch
Dr. Daniel J. Haraf on a Less Toxic Treatment for Patients With Head and Neck Cancer
February 24th 2016Haraf says historically, medical professionals have treated patients with radiation therapy "from their eyebrows to their collarbones." This approach, while effective, has resulted in an abundance of toxicities.
Watch
Chemoradiation Drastically Improves OS for Elderly Patients With Head and Neck Cancers
February 20th 2016The 5-year overall survival (OS) in elderly patients with locally advanced head and neck cancers was drastically improved with concurrent chemoradiation versus radiation therapy alone, according to an analysis of the National Cancer Data Base.
Read More